Skip to main content

Aptose Biosciences Inc(APS-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.35
Day High2.35
Open:2.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
GlobeNewswire
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
Newsfile
Upcoming Meeting Dates - February 16, 2026
GlobeNewswire
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
GlobeNewswire
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
Newsfile
Upcoming Meeting Dates - December 1, 2025
GlobeNewswire
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
GlobeNewswire
Aptose Reports Third Quarter 2025 Results
GlobeNewswire
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
GlobeNewswire
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
GlobeNewswire
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
GlobeNewswire
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
GlobeNewswire
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
GlobeNewswire
Aptose Upgraded to Trade on OTCQB Market
GlobeNewswire
Aptose Announces Deferral of Interest Payment
GlobeNewswire
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose Provides Corporate Updates
GlobeNewswire
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
AI-generated - The Globe and Mail
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (APS)
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
GlobeNewswire
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
GlobeNewswire
Aptose Reports First Quarter 2025 Results
Baystreet
Stocks in play: Aptose Biosciences Inc.
GlobeNewswire
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
AI-generated - The Globe and Mail
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (APS)

Profile

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.